Product Description
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: Orphan Drug - Kidney Diseases *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Advanz Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12620001005943 | N/A |
Completed |
Kidney Diseases |
2022-11-22 |
|
| NCT00063687 | P3 |
Completed |
Heart Failure |
None |